]>
IRCT20200217046523N16 IRCT 2021-06-13 Esfahan University of Medical Sciences gabapentin and pregabalin on neuropathy caused by Chronic Inflammatory Demyelinating Polyradiculoneuropathy Comparative study of the effect of gabapentin and pregabalin on neuropathy caused by Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in patients 2021-08-08 anticipated 40 Complete https://irct.ir/trial/56074 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2-3 Chronic inflammatory demyelinating polyneuropathy. Intervention 1: Intervention group 1: Patients in the first group will be treated with 37.5 mg of venlafaxine daily with 100 to 500 mg of gabapentin daily. This treatment will continue for patients for 12 months. All questionnaires will be completed by patients before the intervention and once every three months for a year (12 months after treatment). Intervention 2: Intervention group 2: Patients in the second group will be treated with 37.5 mg of venlafaxine daily and pregabalin 50 to 300 mg daily. This treatment will continue for patients for 12 months. At the beginning of the intervention, as well as once every three months for a year, all questionnaires for patients will be completed and compared with the other group. Yes - There is a plan to make this available What will be shared: All data can be shared after people have requested. When: Six months after publishing the results. To whom: Academic researchers Conditions: Scientific uses Where to obtain: Website of the Research Committee of Isfahan University of Medical Sciences How to obtain: Clear request on the site to access the data by the individual and then review the request by the research assistant within 2 weeks and then allow access to the data. Comments:
public Keyvan Basiri
No. 22, Roshd Ave., Daneshgah Blvd., Isfahan
Isfahan Iran (Islamic Republic of) 8174673461 +98 31 3668 0042 basirikeivan@gmail.com Esfahan University of Medical Sciences scientific Keyvan Basiri
No. 22, Roshd Ave., Daneshgah Blvd., Esfahan
Esfahan Iran (Islamic Republic of) 8174673461 +98 31 3668 0042 basirikeivan@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) CIDP-induced neuropathy based on neurologist diagnosis Age over 18 years No other underlying disease that causes neuropathy Satisfaction with participation in this study 18 years 70 years Both Hypersensitivity to venlafaxine, gabapentin and pregabalin Dissatisfaction with continuing the study G61 Inflammatory polyneuropathy Treatment - Drugs Treatment - Drugs Intervention group 1: Patients in the first group will be treated with 37.5 mg of venlafaxine daily with 100 to 500 mg of gabapentin daily. This treatment will continue for patients for 12 months. All questionnaires will be completed by patients before the intervention and once every three months for a year (12 months after treatment). Intervention group 2: Patients in the second group will be treated with 37.5 mg of venlafaxine daily and pregabalin 50 to 300 mg daily. This treatment will continue for patients for 12 months. At the beginning of the intervention, as well as once every three months for a year, all questionnaires for patients will be completed and compared with the other group. Intensity of patients' body pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Visual Analogue Scale. Severity of neuropathic pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Short form of McGill Pain Questionnaire (SF-MPQ). Esfahan University of Medical Sciences Approved 2019-05-11 Ethics committee of Esfahan University of Medical Sciences Esfahan University of Medical Sciences, Hezar Jarib Ave., Esfahan Esfahan Isfehan Iran (Islamic Republic of)